Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.

Clinical, Economic, and Patient-Reported Benefits of Connected Insulin Pen Systems: A Systematic Literature Review

Open access

Abstract

The objective of this systematic literature review was to evaluate the available literature concerning the clinical, economic, and patient-reported benefits of insulin pen platforms, including connected insulin pens/caps/sleeves and insulin platforms, as well as mobile apps capable of receiving near real-time insulin dosing information. Medline and Embase databases and the Cochrane Library were searched for published literature between January 2015 and May 2021, and manual searches for conference abstracts from 2018 to May 2021 were performed. These searches were supplemented by internet searches for relevant literature and clinical trials. Study selection involved the population, intervention, comparator, outcomes, time frame, and study design outline. Included studies investigated connected insulin systems or connected caps/sleeves enabling pens to be connected, or apps able to connect to these systems, in individuals of all ages with type 1 or type 2 diabetes mellitus. Searches identified a total of 26 publications (mostly observational studies and conference abstracts) for inclusion, representing ten unique, predominantly small studies. Evidence in this field is still in its early stages, and only two randomized controlled trials met our inclusion criteria. Available results showed that connected insulin pens and their systems potentially helped reduce suboptimal insulin use and may therefore improve glycemic control. Satisfaction of people with diabetes with the technologies used was high, and economic benefits were noted. Features of effective connected insulin pen devices include simplicity of use and data upload/sharing, useful “point-of-care” alerts, and simple and understandable data presentation to facilitate more effective consultations. Connected insulin pen systems could be increasingly considered as part of routine clinical care for insulin-treated persons with diabetes who must manage the complexity of their daily insulin routine. Future research focusing on the way data obtained from these devices can be most effectively used alongside other information is urgently needed. Digital health tools, like text message reminders and mobile apps, are being used more often to help people with diabetes improve their health in a way that works for them. For people who take insulin to treat their diabetes, what has been missing is a way to track insulin doses alongside other diabetes information in an app. Connected insulin pens, also called smart pens, are able to do this. In this article we have looked at the evidence available on the benefits of connected insulin pens. We found that while information on connected insulin pens is limited at the moment, what there is shows that using a connected insulin pen can help people remember to take their insulin and give themselves the right dose and that those who have used a connected insulin pen or related technology are happy with it. Useful features of connected insulin pens include being easy to use, having an alert function, and being able to share the insulin information with the user’s doctor. Connected insulin pens may also reduce diabetes-related costs. Connected insulin pens are likely to become more common for people with diabetes who take insulin, but there is a need for more research on how best to use them to improve the treatment of people with diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12325-023-02478-1

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 PRISMA flow diagram of study selection. PRISMA Preferred Reporting Items for Systematic Reviews and Meta-analyses, RCT randomized controlled trial
Fig. 1 PRISMA flow diagram of study selection. PRISMA Preferred Reporting Items for Systematic Reviews and Meta-analyses, RCT randomized controlled trialCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Research works printed but not linked: 7

  1. International Diabetes Federation. IDF Diabetes Atlas 10th edition. 2021. https://diabetesatlas.org/atlas/tenth-edition/. Accessed Oct 5, 2022.
  2. Christian J, Dasgupta N, Jordan M, Juneja M, Nilsen W, Reites J (2018) Digital health and patient registries: today, tomorrow, and the future. In: Gliklich RE DN, Leavy MB, et al. (ed) 21st century patient registries: registries for evaluating patient outcomes: a user’s guide: 3rd edition, Addendum [Internet]. Agency for Healthcare Research and Quality (US), Rockville (MD).
  3. Eli Lilly and Company. Clinical Study Report: OQV_LY8888AT (Bravo Pen). Indianapolis: Eli Lilly and Company; 2018.
  4. Smith M, Gaetano A, Thanasekaran S, Heungyong IG, Lewis J. Smart insulin pens improve time below range in multiple daily insulin therapy. J Manag Care Spec Pharm. 2021;26(10-a):S35.
  5. Gomez-Peralta F, Abreu C, Gomez-Rodriguez S, Cruz-Bravo M, Alcarria E. Insulclock: a novel insulin delivery optimization and tracking system. Diabetes Technol Ther. 2019;21(Supplement 1):A-69. https://doi.org/10.1089/dia.2019.2525.abstracts. · DOI
  6. Rodbard D, He X, Wang W, et al. Use of connected insulin pen to evaluate the effects of pre-meal, delayed, missed, and correction boluses on prandial glucose control in T1D and T2D. Diabetes Technol Ther. 2021;22(Supplement):A-44-A-45.
  7. Van de Sand L, Schildt J, Thun S. Health economic analysis of the telemedicine based ESYSTA®-System with a connected smart insulin pen – potential monetary savings from using an integrated diabetes management system. Diabetes Technol Ther. 2019;21(Suppl 1):T1.

Cited by

See all 37

Metadata

Authors
Cranston, I., Jamdade, V., Liao, B., & Newson, R. S.
Affiliations
  • Portsmouth Hospitals NHS Trust (GB)
  • Eli Lilly (United States) (US)
  • Eli Lilly (Australia) (AU)
Corresponding author
Newson, Rachel S.
Venue
Advances in Therapy
Published
2023-03-16
Volume
40
Issue
5
Pages
2015-2037
ISSN
  • 0741-238X (ISSN-L)
  • 1865-8652
OpenAlex
W4327681303
Cited by
37
References
44
Citations by year
2026: 14 · 2025: 10 · 2024: 11 · 2023: 2
FWCI
1.33
Type
journal article
Language
en
Open access
Licence
Locations
  • Advances in Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
  • Health Sciences › Health Professions › General Health Professions › Mobile Health and mHealth Applications
Keywords
connected insulin pens, smart pen, insulin dose, type 1 diabetes, type 2 diabetes, glycemic control, patient satisfaction, digital health, mobile application, economic benefits, diabetes technology, data sharing, SMS reminders, insulin-treated patients, diabetes self-management, patient-reported outcomes, health economics, clinical outcomes
MeSH terms
Cost-Benefit Analysis, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Randomized Controlled Trials as Topic, Point-of-Care Systems, Mobile Applications

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical, Economic, and Patient-Reported Benefits of Connected Insulin Pen Systems: A Systematic Literature Review. https://app.cochat.ai/papers/10.1007/s12325-023-02478-1
The paper
Cranston, I., Jamdade, V., Liao, B., & Newson, R. S. (2023). Clinical, Economic, and Patient-Reported Benefits of Connected Insulin Pen Systems: A Systematic Literature Review. Advances in Therapy. https://doi.org/10.1007/s12325-023-02478-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.